Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT – Semaglutide cardiovascular outcomes in overweight or obesity
2017-003380-35Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity and cardiac morbidity comparing Semaglutide 2.4 mg once-weekly with Placebo once-weekly (2 arms). Primary endpoint: Time to first major adverse cardiovascular event (MACE). Started Aug 2018; status: completed.
02
Drugs
03
Conditions
Overweightobesitycardiac morbidity
Beyond the preview
Go deeper on 2017-003380-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003380-35.